Intellia Therapeutics NTLA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$412.69M+20.5% | -$519.02M-7.9% | -$481.19M-1.5% | -$474.19M-77.0% | ||
| $9.78M-4.9% | $10.28M+14.5% | $8.98M+18.5% | $7.57M+9.9% | ||
| $80.22M-48.0% | $154.27M+15.1% | $134.05M+46.7% | $91.4M+94.4% | ||
| —— | -$27.94M-185% | $32.69M— | —— | ||
| $5.99M— | —— | $2.52M— | —— | ||
| —— | —— | —— | $15.92M-7.7% | ||
| $26.35M+608% | -$5.18M-119% | $27.17M+1,158% | $2.16M— | ||
| -$28.11M-27.3% | -$22.08M— | —— | -$63.46M-102% | ||
| $0+100% | -$32.57M— | $0— | $0+100% | ||
| -$394.74M-13.1% | -$348.88M+11.5% | -$394.09M-18.2% | -$333.29M-48.1% | ||
| $1.13M-80.5% | $5.78M-58.7% | $13.99M+3.1% | $13.56M+6.3% | ||
| $228.77M+82.2% | $125.57M— | —— | —— | ||
| $128.18M-27.5% | $176.9M+47.7% | $119.8M— | —— | ||
| $131.49M-29.2% | $185.75M+42.5% | $130.32M-77.6% | $582.96M-20.9% | ||
| —— | —— | —— | $416.88M+1,166% | ||
| $5.86M-67.1% | $17.82M-31.2% | $25.9M— | —— | ||
| $0+100% | -$32.57M— | $0— | $0— | ||
| -$54.95M-206% | -$17.97M-7.8% | -$16.67M-68.7% | -$9.88M-8.5% | ||
| -$33.09M-54.1% | -$21.47M-12.9% | -$19.01M-44.9% | -$13.12M-40.3% | ||
| -$2.81M— | —— | —— | —— | ||
| $26.35M+608% | -$5.18M-119% | $27.17M+1,158% | $2.16M— | ||
| $32K— | —— | —— | —— | ||
| -$28.11M-27.3% | -$22.08M— | —— | -$63.46M-102% | ||
| $0-100% | $112.82M+8,506% | $1.31M-98.0% | $67.05M— | ||
| —— | —— | —— | —— | ||
| -$395.87M-11.6% | -$354.66M+13.1% | -$408.07M-17.7% | -$346.85M-45.9% | ||
| -$395.87M-11.6% | -$354.66M+13.1% | -$408.07M-17.7% | -$346.85M-45.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.